JP2012211164A5 - - Google Patents

Download PDF

Info

Publication number
JP2012211164A5
JP2012211164A5 JP2012138485A JP2012138485A JP2012211164A5 JP 2012211164 A5 JP2012211164 A5 JP 2012211164A5 JP 2012138485 A JP2012138485 A JP 2012138485A JP 2012138485 A JP2012138485 A JP 2012138485A JP 2012211164 A5 JP2012211164 A5 JP 2012211164A5
Authority
JP
Japan
Prior art keywords
val xaa
xaa pro
xau
isomer
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012138485A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012211164A (ja
Filing date
Publication date
Priority claimed from US08/896,394 external-priority patent/US6143721A/en
Application filed filed Critical
Publication of JP2012211164A publication Critical patent/JP2012211164A/ja
Publication of JP2012211164A5 publication Critical patent/JP2012211164A5/ja
Pending legal-status Critical Current

Links

JP2012138485A 1997-07-18 2012-06-20 ドラスタチン15誘導体 Pending JP2012211164A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/896,394 1997-07-18
US08/896,394 US6143721A (en) 1997-07-18 1997-07-18 Dolastatin 15 derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008315263A Division JP5122429B2 (ja) 1997-07-18 2008-12-11 ドラスタチン15誘導体

Publications (2)

Publication Number Publication Date
JP2012211164A JP2012211164A (ja) 2012-11-01
JP2012211164A5 true JP2012211164A5 (enExample) 2013-01-10

Family

ID=25406130

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2000503101A Expired - Fee Related JP4508413B2 (ja) 1997-07-18 1998-07-07 ドラスタチン15誘導体
JP2008315263A Expired - Fee Related JP5122429B2 (ja) 1997-07-18 2008-12-11 ドラスタチン15誘導体
JP2008315269A Expired - Fee Related JP5047935B2 (ja) 1997-07-18 2008-12-11 ドラスタチン15誘導体
JP2012138485A Pending JP2012211164A (ja) 1997-07-18 2012-06-20 ドラスタチン15誘導体

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2000503101A Expired - Fee Related JP4508413B2 (ja) 1997-07-18 1998-07-07 ドラスタチン15誘導体
JP2008315263A Expired - Fee Related JP5122429B2 (ja) 1997-07-18 2008-12-11 ドラスタチン15誘導体
JP2008315269A Expired - Fee Related JP5047935B2 (ja) 1997-07-18 2008-12-11 ドラスタチン15誘導体

Country Status (32)

Country Link
US (6) US6143721A (enExample)
EP (1) EP0991658B1 (enExample)
JP (4) JP4508413B2 (enExample)
KR (1) KR100579748B1 (enExample)
CN (1) CN1268636C (enExample)
AR (1) AR018501A1 (enExample)
AT (1) ATE314387T1 (enExample)
AU (1) AU750120B2 (enExample)
BG (1) BG65212B1 (enExample)
BR (1) BR9810911A (enExample)
CA (1) CA2296036C (enExample)
CO (1) CO4990967A1 (enExample)
CY (1) CY1107047T1 (enExample)
CZ (1) CZ303045B6 (enExample)
DE (1) DE69832982T2 (enExample)
DK (1) DK0991658T3 (enExample)
ES (1) ES2258819T3 (enExample)
HR (1) HRP980397A2 (enExample)
HU (1) HU228996B1 (enExample)
ID (1) ID24669A (enExample)
IL (1) IL133784A (enExample)
MY (1) MY135057A (enExample)
NO (1) NO326827B1 (enExample)
NZ (1) NZ502296A (enExample)
PL (1) PL197884B1 (enExample)
PT (1) PT991658E (enExample)
RU (1) RU2195462C2 (enExample)
SK (1) SK286581B6 (enExample)
TR (2) TR200103545T2 (enExample)
TW (1) TW533217B (enExample)
WO (1) WO1999003879A1 (enExample)
ZA (1) ZA986358B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
AU2001227375A1 (en) 2000-02-08 2001-08-20 Herbert T. Nagasawa N-terminal d(-)-penicillamine peptides as aldehyde sequestration agents
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7192972B2 (en) * 2002-03-22 2007-03-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
DK1545613T3 (da) * 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
CN107213469A (zh) 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
WO2006063135A2 (en) * 2004-12-09 2006-06-15 Eisai R & D Management Co., Ltd. Tubulin isotype screnning in cancer therapy using hemiasterlin analogs
EP1883627B1 (en) 2005-05-18 2018-04-18 Pharmascience Inc. Bir domain binding compounds
WO2007131366A1 (en) 2006-05-16 2007-11-22 Aegera Therapeutics Inc. Iap bir domain binding compounds
CL2008002083A1 (es) 2007-07-16 2008-11-21 Genentech Inc Anticuerpo humanizado anti-cd79b/igbeta/b29; inmunoconjugado; metodo in vitro para determinar presencia de cd79b, inhibir crecimiento de celula con cd79b, o para detectara celula b; metodo para elaborar dicho anticyerpo humanizado; acido nucleico; celula huesped; composicion; metodo de elaboracion de inmunoconjugado; uso medico
NZ583367A (en) 2007-07-16 2012-10-26 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
DE102007039706A1 (de) 2007-08-22 2009-02-26 Erhard Prof. Dr.-Ing. Kohn Chemischer Sensor auf Diamantschichten
ES2643239T3 (es) 2008-01-31 2017-11-21 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
AR079528A1 (es) * 2009-12-18 2012-02-01 Idenix Pharmaceuticals Inc Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
SG182724A1 (en) 2010-02-12 2012-08-30 Pharmascience Inc Iap bir domain binding compounds
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
CN106414465B (zh) 2014-02-28 2021-11-16 杭州多禧生物科技有限公司 带电荷链接体及其在共轭反应上的应用
DK3262071T3 (da) 2014-09-23 2020-06-15 Hoffmann La Roche Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
WO2015151078A2 (en) 2015-06-15 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Hydrophilic linkers for conjugation
NZ739830A (en) 2015-07-12 2021-12-24 Hangzhou Dac Biotech Co Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
CN116143678A (zh) 2016-11-14 2023-05-23 杭州多禧生物科技有限公司 偶联连接体,含有此连接体的细胞结合分子-药物偶联物及其制备和应用
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
WO2022078524A2 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
AU662551B2 (en) * 1991-08-09 1995-09-07 Teikoku Hormone Mfg. Co., Ltd. Novel tetrapeptide derivative
US5533097A (en) * 1992-02-26 1996-07-02 Motorola, Inc. Portable communication system comprising a local and wide area communication units which can store a communication when the wide area communication system is not available
AU3777593A (en) 1992-02-26 1993-09-13 Paul C. Clark System for protecting computers via intelligent tokens or smart cards
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
EP0642530B1 (en) * 1992-05-20 1998-08-12 BASF Aktiengesellschaft Derivatives of dolastatin
PL178766B1 (pl) * 1992-12-16 2000-06-30 Basf Ag Nowe peptydy
US5554993A (en) 1994-01-04 1996-09-10 Panasonic Technologies, Inc. Global position determining system and method
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5554725A (en) * 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5663149A (en) * 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5618232A (en) 1995-03-23 1997-04-08 Martin; John R. Dual mode gaming device methods and systems
US5970143A (en) 1995-11-22 1999-10-19 Walker Asset Management Lp Remote-auditing of computer generated outcomes, authenticated billing and access control, and software metering system using cryptographic and other protocols
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
CA2287379C (en) 1997-01-10 2005-10-04 Silicon Gaming-Nevada Method and apparatus for providing authenticated, secure on-line communication between remote locations
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6554705B1 (en) 1997-08-22 2003-04-29 Blake Cumbers Passive biometric customer identification and tracking system
US6629591B1 (en) 2001-01-12 2003-10-07 Igt Smart token
US6438382B1 (en) 2001-02-14 2002-08-20 Telefonaktiebolaget Lm Ericsson (Publ.) Expedited location determination in analog service areas

Similar Documents

Publication Publication Date Title
JP2012211164A5 (enExample)
JP2016538254A5 (enExample)
JP2007269812A5 (enExample)
JP2010534684A5 (enExample)
SG10201909122QA (en) Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
ES2603058T3 (es) Láminas, esponjas y bayetas revestidas de un tratamiento antimicrobiano
JP2013542247A5 (enExample)
JP2009225798A5 (enExample)
JP2012512907A5 (enExample)
JP2012530060A5 (enExample)
NZ593524A (en) A nonapeptide with anti-tumour activity
JP2012502037A5 (enExample)
JP2015024998A5 (enExample)
JP2015518055A5 (enExample)
JP2014515013A5 (enExample)
JP2009535462A5 (enExample)
JP2011168603A5 (enExample)
JP2013534248A5 (enExample)
JP2008513467A5 (enExample)
JP2011137005A5 (enExample)
EA201071409A1 (ru) Новые соли (4-{[(5-{[(3-хлорфенил)метил]окси}-2-метилфенил)карбонил]амино}-3-метилфенил)уксусной кислоты
CL2008003322A1 (es) Compuestos derivados de acidos de ciclobutanoamino, moduladores de receptores s1p; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento de artritis, enfermedades autoinmunes, diabetes tipo i, enfermedad pulmonar obstructiva cronica, entre otras.
JP2013503110A5 (enExample)
BR112012017691A2 (pt) nova composição
JP2012529293A5 (enExample)